Investigations on molecular determinants of durable molecular response in chronic myeloid leukemia patients
Abstract
Background: Chronic myeloid leukemia (CML), a blood cancer, is caused by translocation between chromosomes 22 and 9 that gives rises to fusion oncogene BCR-ABL. In 20th century, CML was a deadly disease, but tyrosine kinase inhibitors (TKI) led to complete remission in over 80% CML patients. Nevertheless, TKIs are expensive, and discontinuation of treatment is required in patients with very stable treatment response. As no molecular markers of durable TKI response exist, this study was conducted to find out molecular determinants of durable response in CML patients treated with TKIs.
Methods: Peripheral blood and clinical data were collected from CML patients with durable treatment response, along with appropriate controls. DNA was extracted and whole exome sequencing (WES) carried out to screen novel genes mutated only in experimental groups and absent in control groups. Mutations were confirmed using Sanger sequencing. Data was analyzed using SPSS version 23.
Results: Although WES detected 10 genes mutated exclusively in CML patients with durable treatment response, Sanger sequencing could confirm mutations only in RAI1 gene (GC deletion at nucleotides 837-838, a frameshift mutation).
Conclusions: Our study shows that mutations in a novel gene (RAI1) are associated with durable response in CML patients. RAI1 gene is active throughout the body and controls functions of many genes involved in daily rhythms. Our studies provide first important insights into molecular factors associated with long-term treatment response in CML that can serve as novel biomarker to identify patients eligible for TKI cessation in many ongoing CML STOP-TKI trials.
Keywords: CML; TKI therapy; Durable response; Molecular biomarkers; STOP-TKI
Full Text:
PDFReferences
Frazer R, Irvine AE, McMullin MF. Chronic Myeloid Leukaemia in the 21st Century. Ulster Medical Journal, (2007); 76(1): 8-17.
Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, et al. The Philadelphia chromosome in leukemogenesis. Chinese Journal of Cancer, (2016); 35:48.
Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, et al. Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia. Blood Cancer Journal, (2017); 7(4): e559.
Pophali PA, Patnaik MM. The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Cancer Journal. (2016); 22(1): 40-50.
Haznedaroglu IC. Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML). Mediterranean Journal of Hematology and Infectious Diseases. (2014); 6(1): e2014009.
Ben Hassine I, Gharbi H, Soltani I, Teber M, Farrah A, Ben Hadj Othman H, et al. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology, (2017) ; 79(4): 737-745.
Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, et al. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. Journal of Clinical Oncology, (2017); 35(2): 166-174.
D Irani YD, Hughes A, Clarson J, Kok CH, Shanmuganathan N, White DL, et al. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. British Journal of Haematology, (2020); 191(3): 433-441.
D Makhtar SM, Husin A, Baba AA, Ankathil R. Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients. Journal of Genetics, (2018); 97(4): 835-842.
D Shih YT, Cortes JE, Kantarjian HM. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematology, (2019); 6(8): e398-e408.
Saußele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia, (2016); 30(8): 1638-47.
Gong Z, Zheng L, Tang Z, Chen Z, Wang W, Bai S, et al. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Annals of Hematology, (2017); 96(3): 501-504.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood, (2013); 122(6): 872-884
Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, et al. Staging of chronic myeloid leukemia in the imatinib era: An evaluation of the World Health Organization proposal. Cancer, (2006); 106(6): 1306-1315.
Kaplan E and Meier P. Nonparanietric estimation from incomplete observations. Journal of the American Statistical Association, (1958); 53(282): 457-481.
Goodyear MD, Krleza-Jeric K, Lemmens T. The Declaration of Helsinki. The BMJ, (2007); 335(7621): 624-5.
Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood, (1984); 63(4): 789-799.
Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood, (2006); 108(6): 1809-1820.
Cumbo C, Impera L, Minervini CF, Orsini P, Anelli L, Zagaria A, et al. Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients. Oncotarget, (2018); 9(13): 10978-10986.
Al-Asiri S, Basit S, Wood-Trageser MA, Yatsenko SA, Jeffries EP, Surti U, et al. Exome sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability. Journal of Clinical Investigation, (2015); 125(1): 258-262.
Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. The Journal of Molecular Diagnostics, (2010); 4: 425-432.
Slager RE, Newton TL, Vlangos CN, Finucane B, Elsea SH. Mutations in RAI1 associated with Smith-Magenis syndrome. Nature Genetics, (2003); 33(4): 466-8.
Kuntegowdanahalli LC, Kanakasetty GB, Thanky AH, Dasappa L, Jacob LA, Mallekavu SB, et al. Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era-experience from a tertiary oncology centre in Southern India. Ecancermedicalscience, (2016); 10: 679.
Bansal S, Prabhash K, Parikh P. Chronic myeloid leukemia data from India. Indian Journal of Medical and Paediatric Oncology, (2013); 34(3): 154–158.
Zaidi U, Kaleem B, Borhany M, Maqsood S, Fatima N, Sufaida G, et al. Early and durable deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients. Cancer Management Research, (2019); 11: 1493-1502.
de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of durable responses in an intention-to-treat analysis. Journal of Clinical Oncology, (2008); 26(20): 3358-63.
Rousselot P, Cony-Makhoul P, Nicolini F, Mahon FX, Berthou C, Réa D, et al. Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study. American Journal of Hematology, (2013); 88(1): 1-4.
Heibl S, Buxhofer-Ausch V, Schmidt S, Webersinke G, Lion T, Piringer G, et al. A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1. Hematological Oncology, (2020); 38(5): 792-798.
Milojkovic D, Cross NCP, Ali S, Byrne J, Campbell G, Dignan FL, et al. Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. British Journal of Haematology, (2021); 192(1): 62-74
Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. American Journal of Hematology, (2019); 94(3): 346-357.
Irani YD, Hughes A, Clarson J, Kok CH, Shanmuganathan N, White DL, et al. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. British Journal of Haematology, (2020); 191(3): 433-441.
Fragoso YD, Stoney PN, Shearer KD, Sementilli A, Nanescu SE, Sementilli P, et al. Expression in the human brain of retinoic acid induced 1, a protein associated with neurobehavioural disorders. Brain Structure and Function, (2015); 220(2): 1195-203.
Vilboux T, Ciccone C, Blancato JK, Cox GF, Deshpande C, Introne WJ, et al. Molecular analysis of the Retinoic Acid Induced 1 gene (RAI1) in patients with suspected Smith-Magenis syndrome without the 17p11.2 deletion. PLoS One. (20110; 6(8): e22861.
Ricard G, Molina J, Chrast J, Gu W, Gheldof N, Pradervand S, et al. Phenotypic consequences of copy number variation: insights from Smith-Magenis and Potocki-Lupski syndrome mouse models. PLoS Biology, (2010); 8(11): e1000543.
Yan J, Bi W, Lupski JR. Penetrance of craniofacial anomalies in mouse models of Smith-Magenis syndrome is modified by genomic sequence surrounding Rai1: not all null alleles are alike. American Journal of Human Genetics, (2007); 80(3): 518–525
Bi W, Yan J, Shi X, Yuva-Paylor LA, Antalffy BA, Goldman A, et al. Rai1 deficiency in mice causes learning impairment and motor dysfunction, whereas Rai1 heterozygous mice display minimal behavioral phenotypes. Human Molecular Genetics, (2007); 16(15): 1802-13.
Chen L, Tao Y, Song F, Yuan X, Wang J, Saffen D. Evidence for genetic regulation of mRNA expression of the dosage-sensitive gene retinoic acid induced-1 (RAI1) in human brain. Scientific Reports, (2016); 6: 19010.
Vulto-van Silfhout AT, Rajamanickam S, Jensik PJ, Vergult S, de Rocker N, Newhall KJ, et al. Mutations affecting the SAND domain of DEAF1 cause intellectual disability with severe speech impairment and behavioral problems. American Journal of Human Genetics, (2014); 94(5): 649-61.
Berger SI, Ciccone C, Simon KL, Malicdan MC, Vilboux T, Billington C, et al. Exome analysis of Smith-Magenis-like syndrome cohort identifies de novo likely pathogenic variants. Human Genetics, (2017); 136(4): 409–420.
Makhtar SM, Husin A, Baba AA, Ankathil R. Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients. Journal of Genetics, (2018); 97(4): 835-842.
Refbacks
- There are currently no refbacks.